KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Goodwill Amortization of Goodwill Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Divestments Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Zimmer Biomet Holdings (ZBH) Change in Cash (2016 - 2026)

Zimmer Biomet Holdings has reported Change in Cash over the past 18 years, most recently at -$167.7 million for Q1 2026.

For Q1 2026, Change in Cash fell 119.52% year-over-year to -$167.7 million; the TTM value through Mar 2026 reached -$960.4 million, down 196.86%, while the annual FY2025 figure was $66.4 million, 39.47% down from the prior year.
Change in Cash for Q1 2026 was -$167.7 million at Zimmer Biomet Holdings, up from -$700.8 million in the prior quarter.
Over five years, Change in Cash peaked at $859.1 million in Q1 2025 and troughed at -$827.7 million in Q2 2025.
A 5-year average of -$3.2 million and a median of -$27.6 million in 2023 define the central range for Change in Cash.
On a YoY basis, Change in Cash climbed as much as 3884.58% in 2025 and fell as far as 3154.24% in 2025.
Year by year, Change in Cash stood at -$169.7 million in 2022, then surged by 172.83% to $123.6 million in 2023, then tumbled by 135.28% to -$43.6 million in 2024, then plummeted by 1507.34% to -$700.8 million in 2025, then skyrocketed by 76.07% to -$167.7 million in 2026.
Business Quant data shows Change in Cash for ZBH at -$167.7 million in Q1 2026, -$700.8 million in Q4 2025, and $735.8 million in Q3 2025.